期刊文献+

人可溶性APRIL突变体的原核表达与纯化

Prokaryotic expression and purification of human soluble APRIL mutants
下载PDF
导出
摘要 目的制备人可溶性增殖诱导配体(soluble a proliferation inducing ligand,sAPRIL)的两种突变体,为寻找APRIL的竞争抑制剂创造条件。方法采用一步反向PCR法,以人APRIL第186位甘氨酸(186G)和187位谷氨酰胺(187Q)残基为突变位点,构建如下两个突变体DNA,即sAPRIL突变体-1(mutant sAPRIL-1,msAPRIL-1)DNA(186G被赖氨酸残基K置换,187Q缺失)和msAPRIL-2 DNA(186G187Q置换为186K187G);测序后将两突变体DNA分别亚克隆于原核表达载体pQE-80L,继而在大肠杆菌DH5α中表达相应突变体蛋白,经SDS-PAGE和Western blot鉴定表达产物,经Ni2+-NTA和Sephadex G-75柱层析纯化相应突变体蛋白。结果一步反向PCR结合DNA测序,得到了与上述设计一致的两个sAPRIL突变体DNA。将两突变体DNA分别亚克隆于pQE-80L后,在大肠杆菌DH5α中成功表达了相应突变体蛋白。经Ni2+-NTA柱层析成功地纯化了两突变体蛋白,经Sephadex G-75柱层析成功获得了两突变体蛋白的三聚体分子。结论成功制备了sAPRIL的两种突变体蛋白,为寻找基于sA-PRIL突变体的抗肿瘤分子奠定了基础。 Objective To generate two mutants of human soluble APRIL(sAPRIL) for laying a foundation for developing competitive inhibitor of a proliferation inducing ligand(APRIL). Methods Taking 186G and 187Q of human APRIL as mutation sites, one-step opposite orientation PCR was used to construct the two mutant sAPRIL(msAPRIL) DNAs, namely msAPRIL-1 DNA(in which 186G was replaced by K while 187Q was deleted) and msAPRIL-2 DNA(in which 186G187Q was replaced by 186K187G). The two sequenced msAPRIL DNAs were separately subcloned into the prokaryotic expression vector pQE-80L, and the corresponding recombinant msAPRIL proteins were expressed in E. coli DH5α. The expressed msAPRIL proteins were analyzed by SDS-PAGE and Western blotting, and purified by Ni^2+ -NTA and Sephadex G-75 chromatography. Results By using one-step opposite orientation PCR, the two msAPRIL DNAs were cloned, and their sequences were consistent with the designed mutation, After inserting every msAPRIL DNA into pQE-80L vector respectively, the recombinant msAPRIL proteins were successfully expressed in E. coli DH5α. The msAPRIL proteins were purified effectively; the homotrimers of msAPRILs were isolated by Sephadex G-75. Conclusion Two msAPRIL proteins are successfully prepared, which might pave a way for developing novel antitumor therapeutics based on mutant sAPRIL.
出处 《免疫学杂志》 CAS CSCD 北大核心 2007年第6期636-639,644,共5页 Immunological Journal
基金 重庆市科委科学基金计划资助项目(CSTC 2006BB5110) 第三军医大学科研基金资助项目(SG200538)
关键词 增殖诱导配体 突变体 原核表达 肿瘤 A proliferation inducing ligand Mutant Prokaryotic expression Tumor
  • 引文网络
  • 相关文献

参考文献11

  • 1Hahne M,Kataoka T,Schorter M,et al.APRIL,a new ligand of the tumor necrosis factor family,stimulates tumor cell growth[J].J Exp Med,1998,188(6):1 185-1 190. 被引量:1
  • 2Phillips TA,Ni J,Hunt JS.Cell-specific expression of B lymphocyte (APRIl,BLyS)-and Th2 (CD30L/CD153)-promoting tumor necrosis factor superfamily ligands in human placentas[J].J Leukoc Biol,2003,74(1):81-87. 被引量:1
  • 3Mackay F,Ambrose C.The TNF family members BAFF and APRIL:the growing complexity[J].Cytokine Growth Factor Rev,2003,14(3):311-324. 被引量:1
  • 4He B,Raab-Traub N,Casali P,et al.EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching[J].J Immunol,2003,171(10):5 215-5 224. 被引量:1
  • 5Liu Y,Xu L,Opalka N,et al.Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands[J].Cell,2002,108(3):383-394. 被引量:1
  • 6戴双双,何凤田,杨朝辉,彭家和,李蓉芬,张艳,陈麟凤.人可溶性APRIL基因的克隆、表达及生物学活性检测[J].中国生物化学与分子生物学报,2005,21(1):61-64. 被引量:5
  • 7高会广,何凤田,府伟灵,李蓉芬,陈麟凤,卞爱娜,吉清,戴双双.人BLyS免疫抑制分子的克隆、表达及纯化[J].免疫学杂志,2005,21(5):370-373. 被引量:1
  • 8Mhawech Fauceglia P,Kaya G,Sauter G,et al.The source of APRIL up-regulation in human solid tumor lesions[J].J Leukoc Biol,2006,80(4):697-704. 被引量:1
  • 9Dillon SR,Gross JA,Ansell SM,et al.An APRIL to remember:novel TNF ligands as therapeutic targets[J].Nat Rev Drug Discov,2006,5(3):235-246. 被引量:1
  • 10Kelly K,Manos E,Jensen G,et al.APRIL/TRDL-1,atumor necrosis factor-like ligand,stimulates cell death[J].Cancer Res,2000,60(4):1 021-1 027. 被引量:1

二级参考文献25

  • 1Sambrook J Russell D W著 黄培堂等译.分子克隆实验指南 第3版[M].北京:科学出版社,2002,1.84-85. 被引量:2
  • 2Roschke V, Sosnovtseva S, Christopher D, Hong JS, Smith R, Albert V, Ullrinh S, Nardelli B, Hilbert D M, Stohl W. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol, 2002,169(8):4314 ~ 4321 被引量:1
  • 3Stein J V, Lopez-Fraga M, Elustondo FA, Carla E, Hahne M.. APRIL modulates B and T cell immunity. J Clin Invest, 2002,109(12): 1587~ 1598 被引量:1
  • 4Marsters S A, Minhong Yan, Pitti R M, Philip E, Haas, Dixit V M,Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol, 2000, 10(13) :785 ~ 788 被引量:1
  • 5Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C,Moine P, Rossi JF, Klein B, Tarte K. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004,103(8): 3148 ~ 3157 被引量:1
  • 6Bonci D, Hahne M, Felli N, Peschle C, De Maria R. Potential role of APRIL as autocrine growth factor for megakaryocytopoiesis. Blood,2004, [Epub ahead of print] 被引量:1
  • 7Stohl W, Metyas S, Tan S M, Cheema G S, Oamar B, Roschke V, Wu Y, Baker K P, Hilbert D M. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis, 2004,63 (9): 1096 ~1103 被引量:1
  • 8Medema J P, Planelles-Carazo L, Hardenberg G, Hahne M. The uncertain glory of APRIL. Cell Death Differ, 2003,10(6): 1121 ~ 1125 被引量:1
  • 9Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M,McCabe S, Qiu W R, Kornuc M, Xia X Z, Guo J, Stolina M, Boyle W J, Sarosi I, Hsu H, Senaldi G, Theill L E. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity.Nat Immunol. 2000 ,1( 3 ) :252~ 256 被引量:1
  • 10Rennert P, Schneider P, Cachero T G, Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C, Strauch K, Browning J L, Ambrose C, Tschopp J. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med , 2000,192(11):1677 ~ 1684 被引量:1

共引文献4

;
使用帮助 返回顶部